Concepedia

Author

Stefani Parmentier

Rems-Murr-Klinikum

Also Known As

J. R. Göthert, S Parmentier, S. Parmentier, Stefani B Parmentier, Stefani B. Parmentier, Stefani Barbara Parmentier, Stefani Parmentier, T. Geer

69

Publications

1.3K

Citations

16

H-Index

13

Concepts

All Affiliations

Rems-Murr-KlinikumTechnische Universität DresdenGoethe University FrankfurtHeidelberg UniversityKlinik und Poliklinik für Psychotherapie und Psychosomatik
SP

About

Stefani Parmentier is an author at Rems-Murr-Klinikum specializing in hematology, medicine, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

482

2

Health Sciences

2

2

432

3

Marrow Transplantation

2

2

77

4

Cellular Therapies

1

1

37

5

Immunology

1

1

40

Stefani Parmentier

×

17

Publications

979

Citations

14

H-Index

YearCitations

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann,

The Lancet Oncology

2015

395

Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome

Felix von Dalowski, Michael Krämer, Martin Wermke,

Stem Cells

2015

93

High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial

Markus Schaich, Stefani Parmentier, Michael Krämer,

Journal of Clinical Oncology

2013

81

The prevalence of extramedullary acute myeloid leukemia detected by <sup>18</sup>FDG-PET/CT: final results from the prospective PETAML trial

Friedrich Stölzel, Tors Lüer, Steffen Löck,

Haematologica

2019

58

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

Christoph Röllig, Hubert Serve, Richard Noppeney,

Leukemia

2021

57

Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial

Christoph Röllig, Carsten Müller‐Tidow, Andreas Hüttmann,

Blood

2014

48

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Matthias Stelljes, Jan Moritz Middeke, Gesine Bug,

The Lancet Haematology

2024

44

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

Johannes Schetelig, Markus Schaich, K. Schäfer-Eckart,

Leukemia

2014

40

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

Jan Moritz Middeke, Regina Herbst, Stefani Parmentier,

Leukemia

2015

37

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry

Judith Gecht, Ioannis Tsoukakis, Kim Kricheldorf,

Cancers

2021

23

Page 1